Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H13N3O.C4H4O4 |
| Molecular Weight | 319.3126 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CN[C@H]1CN2C(=O)NC3=C2C(C1)=CC=C3
InChI
InChIKey=VOJRMYBBPKNLLI-ORHWHDKWSA-N
InChI=1S/C11H13N3O.C4H4O4/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9;5-3(6)1-2-4(7)8/h2-4,8,12H,5-6H2,1H3,(H,13,15);1-2H,(H,5,6)(H,7,8)/b;2-1-/t8-;/m1./s1
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | C11H13N3O |
| Molecular Weight | 203.2404 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Sumanirole is a novel dopamine agonist with high affinity and efficacy at D2 dopamine receptors and has a substantial degree of selectivity for the D2 receptor over other dopamine receptor subtypes. It had been in clinical trials for the treatment of Parkinson’s disease and restless leg syndrome but these studies were terminated for the efficacy reason.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL339 |
12.0 nM [Ki] | ||
Target ID: CHEMBL3138 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9057850 |
1.9 µM [Ki] | ||
Target ID: CHEMBL273 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9057850 |
92.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 mg 1 times / day multiple, oral Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: dizziness, Headaches... AEs leading to discontinuation/dose reduction: dizziness (1 pt) Sources: Headaches (1 pt) |
2 mg 1 times / day multiple, oral Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: dizziness, diarrhea... AEs leading to discontinuation/dose reduction: dizziness (1 pt) Sources: diarrhea (1 pt) Nausea and vomiting (1 pt) Dizziness (1 pt) insomnia (1 pt) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Headaches | 1 pt Disc. AE |
1 mg 1 times / day multiple, oral Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| dizziness | 1 pt Disc. AE |
1 mg 1 times / day multiple, oral Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| Dizziness | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| Nausea and vomiting | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| diarrhea | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| dizziness | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| insomnia | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Asymmetric synthesis of tetrahydroquinolin-3-ols via CoCl2-catalyzed reductive cyclization of nitro cyclic sulfites with NaBH4. | 2009-02-19 |
|
| Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. | 2007-08 |
|
| Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs. | 2006-03 |
|
| Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. | 2005-09 |
|
| The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. | 2005-09 |
|
| Dopamine receptor agonists differ in their actions on cardiac ion channels. | 2003-12-15 |
|
| Sumanirole Pharmacia. | 2003-01 |
|
| Effects of selective activation of dopamine D2 and D3 receptors on prolactin secretion and the activity of tuberoinfundibular dopamine neurons. | 1997-09-17 |
|
| U-95666E: a potential anti-parkinsonian drug with anxiolytic activity. | 1997-07 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17318839
1 to 16 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15980060
Sumanirole activated D2 receptor-stimulated mitogenesis with an EC50 of 4.6 nM, but it had no activity at D3 and D4 receptors in measurements of receptor-activated mitogenesis at concentrations up to 1 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:28:23 GMT 2025
by
admin
on
Mon Mar 31 21:28:23 GMT 2025
|
| Record UNII |
2OI87T3R1B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DBSALT002019
Created by
admin on Mon Mar 31 21:28:23 GMT 2025 , Edited by admin on Mon Mar 31 21:28:23 GMT 2025
|
PRIMARY | |||
|
179386-44-8
Created by
admin on Mon Mar 31 21:28:23 GMT 2025 , Edited by admin on Mon Mar 31 21:28:23 GMT 2025
|
PRIMARY | |||
|
C108539
Created by
admin on Mon Mar 31 21:28:23 GMT 2025 , Edited by admin on Mon Mar 31 21:28:23 GMT 2025
|
PRIMARY | |||
|
2OI87T3R1B
Created by
admin on Mon Mar 31 21:28:23 GMT 2025 , Edited by admin on Mon Mar 31 21:28:23 GMT 2025
|
PRIMARY | |||
|
9818478
Created by
admin on Mon Mar 31 21:28:23 GMT 2025 , Edited by admin on Mon Mar 31 21:28:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |